01—Abstract
Summary
Summary of the 8-K filed July 29, 2026. Cited figures are marked; the original filing is the authoritative source.
IDEX Corporation reported second-quarter 2026 results on July 29, 2026, with record sales of $921 milliona, up 6% on a reported basis and 5% organically.
Net sales were $920.6 millionb versus $865.4 million a year earlier. Reported diluted EPS was $1.93, up from $1.74, and adjusted diluted EPS was a record $2.32, up 12% from $2.07. Record orders exceeded $1 billion ("$1,071.6 million"), up 29% on a reported basis and 28% organically.
Health & Science Technologies drove growth, with net sales up 14% and organic sales up 12%, driven by AI-related data center power and semiconductor demand, space and defense, and positive price. The quarter included a net benefit from IEEPA tariff refunds. The filing says these refunds contributed 150 basis points to gross margin and added $0.08c to both reported and adjusted diluted EPS, partly offset by a $14.7 million reduction in net sales from expected customer rebates tied to the refunds.
Operating cash flow was $200.0 milliond and free cash flow was $177.0 million, up from $146.9 million. The company returned $77 million through share repurchases and paid $54 million in dividends during the quarter. Management raised its full-year 2026 guidance, now projecting organic sales growth of 5% to 6% (previously 3% to 4%) and adjusted diluted EPS of $8.70 to $8.85 (previously $8.35 to $8.55).
Third-quarter guidance calls for organic sales growth of 5% to 7% and adjusted diluted EPS of $2.20 to $2.25. The filing attributes the raised outlook to strong year-to-date performance and improved second-half visibility.
02—Key points
Key Highlights
- Record quarterly sales of $920.6 million, up 6% reported and 5% organic; record orders of $1,071.6 million, up 29% reported and 28% organic.
- Reported diluted EPS of $1.93 (up from $1.74); record adjusted diluted EPS of $2.32 (up from $2.07).
- Health & Science Technologies net sales rose 14% (12% organic), driven by AI-related data center power and semiconductor demand.
- IEEPA tariff refunds added 150 basis points to gross margin and $0.08 to diluted EPS, partly offset by a $14.7 million reduction in net sales from expected customer rebates.
- Free cash flow of $177.0 million (103% conversion) versus $146.9 million a year earlier; $77 million of share repurchases and $54 million of dividends in the quarter.
- Full-year 2026 guidance raised: organic sales growth of 5% to 6% (from 3% to 4%) and adjusted diluted EPS of $8.70 to $8.85 (from $8.35 to $8.55).
- Fire & Safety/Diversified Products net sales declined 1%, with lower European rescue demand and Dispensing volumes.
03—Questions
Frequently Asked Questions
Why did IDEX raise its full-year 2026 guidance?
The filing says the increase reflects strong performance year-to-date and improved visibility in the second half of the fiscal year. Full-year organic sales growth is now projected at 5% to 6%, up from 3% to 4%, and adjusted diluted EPS at $8.70 to $8.85, up from $8.35 to $8.55.
How much of the quarter's earnings came from IEEPA tariff refunds?
The filing states that IEEPA tariff refunds benefited adjusted diluted EPS by $0.08 in the second quarter, and contributed 150 basis points to gross margin. These benefits were partly offset by a $14.7 million reduction in net sales from expected customer rebates tied to the refunds.
What drove demand strength in the quarter?
Record orders of over $1 billion rose 28% organically. The filing attributes Health & Science Technologies growth primarily to AI-driven demand for data center power and semiconductor markets, along with strength in space and defense. Fluid & Metering Technologies had higher volumes in municipal water, semiconductor and mining markets, offset by lower volumes in energy, agriculture and chemical markets.
How did IDEX deploy capital in the second quarter?
IDEX returned capital to shareholders through $77 million of share repurchases and $54 million of dividends in the quarter. Operating cash flow was $200.0 million and free cash flow was $177.0 million, and the company spent $23.0 million on capital expenditures.
04—Continue